Other veterinarians with experience using CBD in dogs also reported seeing positive results using the drug for canine osteoarthritis.
Researchers from Baylor College of Medicine worked in collaboration with the CBD brand Medterra on the randomized, double-blind, placebo-controlled study. The 4 week study included 20 large dogs diagnosed with osteoarthritis who were randomly assigned to receive either a placebo or one of three different CBD options. The dogs were evaluated before and after the regimen by both veterinarians and their owners on factors related to their mobility and pain. Details about the amount of CBD each dog was taking was kept from the owners and veterinarians so that it wouldn’t influence their evaluations.
“I openly admit that I was surprised at how quickly we saw such large results” says Matthew Halpert PhD, Faculty with the Department of Pathology and Immunology at Baylor College of Medicine and Senior Scientific Advisor for Medterra. “I would not have expected to see too much of anything in just one month.”
White Sox And Yankees On Deck For Field Of Dreams Game
Brett Hartmann gives his dogs Cayley, a six-year-old-Labrador Retriever drops of a cannabis based . [+] medicinal tincture to treat hip pain and anxiety. New research supports CBD for canine osteoarthritis.
AFP via Getty Images
Halpert, who designed the experiment, explains that in the placebo and lower dose groups, the owners reported their dogs to be “just as miserable as before” and veterinarians didn’t see any improvement in the dog’s mobility. But in the two higher dose groups “almost every dog saw significant improvement in their conditions, in regards to reduced pain and increased ability to move around. And the dogs seemed happier and were able to do more.”
Still, Cital supports the use of CBD for dogs with osteoarthritis and has even had his own success story, using CBD to treat his own 11 year old mixed breed dog, who was having shaking in his back legs and a hard time getting up the stairs.
Cannabidiol (CBD) is one of the major nonpsychoactive cannabinoids produced by Cannabis sativa L. Recent studies have shown that CBD has a high protective index, comparable to that of phenobarbital and phenytoin. Because CBD has been reported to possess both anticonvulsant and antiepileptic activity, its pharmacokinetics were studied in dogs after the administration of two iv doses (45 and 90 mg) and one oral dose (180 mg) to dogs. After iv administration, CBD was rapidly distributed, followed by a prolonged elimination. It has a terminal half-life of 9 hr. CBD plasma levels declined in a triphasic fashion. The total body clearance of CBD was 17 liters/hr (after the 45-mg dose) and 16 liters/hr (after the 90-mg dose). This clearance value, after its normalization to blood clearance using mathematical equations, approaches the value of the hepatic blood flow; the extraction ratio in the liver is 0.74. CBD was observed to have a large volume of distribution, approximately 100 liters. In the dose range of 45 to 90 mg, the increase in the AUC was proportional to the dose, a fact that indicates that the pharmacokinetic profile of CBD in this dose range was not dose dependent. In three of the six dogs studied, CBD could not be detected in the plasma after oral administration. In the other three, the oral bioavailability ranged from 13 to 19%. The results of this study show that CBD is barely absorbed after oral administration to dogs. This low bioavailability may be due to a first pass effect.